Resultados da pesquisa - Yoshitaka Narita

Refinar resultados
  1. 1
    Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors

    Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors Por Yoshitaka Narita

    Publicado em 2013
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  2. 2
    Bevacizumab for glioblastoma

    Bevacizumab for glioblastoma Por Yoshitaka Narita

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  3. 3
    Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001–2004 from the Brain Tumor Registry of Japan

    Trends and Outcomes in the Treatment of Gliomas Based on Data during 2001–2004 from the Brain Tumor Registry of Japan Por Yoshitaka Narita, Soichiro Shibui

    Publicado em 2015
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  4. 4
    Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma

    Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma Por Kaishi Satomi, Makoto Ohno, Yuko Matsushita, Masamichi Takahashi, Yasuji Miyakita, Yoshitaka Narita, Koichi Ichimura, Akihiko Yoshida

    Publicado em 2020
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  5. 5
    In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy

    In Vivo Study of the Efficacy and Safety of 5-Aminolevulinic Radiodynamic Therapy for Glioblastoma Fractionated Radiotherapy Por Junko Takahashi, Shinsuke Nagasawa, Motomichi Doi, Masamichi Takahashi, Yoshitaka Narita, Junkoh Yamamoto, Mitsushi Ikemoto, Hitoshi Iwahashi

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  6. 6
    Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study

    Accelerator-based BNCT for patients with recurrent glioblastoma: a multicenter phase II study Por Shinji Kawabata, Minoru Suzuki, Katsumi Hirose, Hiroki Tanaka, Takahiro Katō, Hiromi Goto, Yoshitaka Narita, Shin‐Ichi Miyatake

    Publicado em 2021
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  7. 7
    Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells

    Pivotal role for ROS activation of p38 MAPK in the control of differentiation and tumor-initiating capacity of glioma-initiating cells Por Atsushi Sato, Masashi Okada, Keita Shibuya, Eriko Watanabe, Shizuka Seino, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  8. 8
    High Level Calcineurin Activity Predisposes Neuronal Cells to Apoptosis

    High Level Calcineurin Activity Predisposes Neuronal Cells to Apoptosis Por Akio Asai, Jianhua Qiu, Yoshitaka Narita, Shunji Chi, Nobuhito Saito, Nobusada Shinoura, Hirofumi Hamada, Yoshiyuki Kuchino, Takaaki Kirino

    Publicado em 1999
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  9. 9
    Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study

    Safety and efficacy of tumour-treating fields (TTFields) therapy for newly diagnosed glioblastoma in Japanese patients using the Novo-TTF System: a prospective post-approval study Por Ryo Nishikawa, Fumiyuki Yamasaki, Yoshiki Arakawa, Yoshihiro Muragaki, Yoshitaka Narita, Shota Tanaka, Shigeru Yamaguchi, Akitake Mukasa, Masayuki Kanamori

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  10. 10
    IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy

    IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy Por Yoshiko Okita, Yoshitaka Narita, Yasuji Miyakita, Makoto Ohno, Yuko Matsushita, Shintaro Fukushima, Minako Sumi, Koichi Ichimura, Takamasa Kayama, Soichiro Shibui

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  11. 11
    Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells

    Resveratrol promotes proteasome-dependent degradation of Nanog via p53 activation and induces differentiation of glioma stem cells Por Atsushi Satō, Masashi Okada, Keita Shibuya, Eriko Watanabe, Shizuka Seino, Kaori Suzuki, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka

    Publicado em 2013
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  12. 12
    Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas

    Erratum to: Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas Por Hideyuki Arita, Yoshitaka Narita, Yuko Matsushita, Shintaro Fukushima, Akihiko Yoshida, Hirokazu Takami, Yasuji Miyakita, Makoto Ohno, Soichiro Shibui, Koichi Ichimura

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Errata/Corrigenda
    Adic. favoritos
    Na minha lista:
  13. 13
    Childhood, adolescent and young adult cancer incidence in Japan in 2009–2011

    Childhood, adolescent and young adult cancer incidence in Japan in 2009–2011 Por Kota Katanoda, Akiko Shibata, Tomohiro Matsuda, Megumi Hori, Kayo Nakata, Yoshitaka Narita, Chitose Ogawa, Wataru Munakata, Akira Kawai, Hiroshi Nishimoto

    Publicado em 2017
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  14. 14
    Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma

    Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma Por Shoichi Deguchi, Fumiharu Ohka, Yoshiki Shiba, Junya Yamaguchi, Aya Sato, Keiko Shinjo, Yoshiki Arakawa, Yoshitaka Narita, Yutaka Kondo, Ryuta Saito

    Publicado em 2025
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  15. 15
    Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence

    Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence Por Daisuke Kawauchi, Makoto Ohno, Mai Honda‐Kitahara, Yasuji Miyakita, Masamichi Takahashi, Shunsuke Yanagisawa, Yukie Tamura, Miyu Kikuchi, Koichi Ichimura, Yoshitaka Narita

    Publicado em 2023
    Obter o texto integral Obter o texto integral
    Revisão
    Adic. favoritos
    Na minha lista:
  16. 16
    Revisiting <scp><i>TP</i></scp><i>53</i> Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas

    Revisiting <scp><i>TP</i></scp><i>53</i> Mutations and Immunohistochemistry—A Comparative Study in 157 Diffuse Gliomas Por Hirokazu Takami, Akihiko Yoshida, Shintaro Fukushima, Hideyuki Arita, Yuko Matsushita, Taishi Nakamura, Makoto Ohno, Yasuji Miyakita, Soichiro Shibui, Yoshitaka Narita, Koichi Ichimura

    Publicado em 2014
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  17. 17
    Targeting JNK for therapeutic depletion of stem-like glioblastoma cells

    Targeting JNK for therapeutic depletion of stem-like glioblastoma cells Por Kenichiro Matsuda, Atsushi Satō, Masashi Okada, Keita Shibuya, Shizuka Seino, Kaori Suzuki, Eriko Watanabe, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  18. 18
    Significance of <i>IDH</i> mutations varies with tumor histology, grade, and genetics in Japanese glioma patients

    Significance of <i>IDH</i> mutations varies with tumor histology, grade, and genetics in Japanese glioma patients Por Akitake Mukasa, Shunsaku Takayanagi, Kuniaki Saito, Junji Shibahara, Yusuke Tabei, Kazuhide Furuya, Takafumi Ide, Yoshitaka Narita, Ryo Nishikawa, Keisuke Ueki, Nobuhito Saito

    Publicado em 2011
    Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  19. 19
    Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells

    Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells Por Jun Sunayama, Kenichiro Matsuda, Atsushi Satō, Ken Tachibana, Kaori Suzuki, Yoshitaka Narita, Soichiro Shibui, Kaori Sakurada, Takamasa Kayama, Arata Tomiyama, Chifumi Kitanaka

    Publicado em 2010
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:
  20. 20
    Glioma-Initiating Cell Elimination by Metformin Activation of FOXO3 via AMPK

    Glioma-Initiating Cell Elimination by Metformin Activation of FOXO3 via AMPK Por Atsushi Sato, Jun Sunayama, Masashi Okada, Eriko Watanabe, Shizuka Seino, Keita Shibuya, Kaori Suzuki, Yoshitaka Narita, Soichiro Shibui, Takamasa Kayama, Chifumi Kitanaka

    Publicado em 2012
    Obter o texto integral Obter o texto integral
    Artigo
    Adic. favoritos
    Na minha lista:

Ferramentas de pesquisa: